Medroxyprogesterone Acetate
"Medroxyprogesterone Acetate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.
| Descriptor ID |
D017258
|
| MeSH Number(s) |
D04.210.500.745.745.654.829.395.700.500
|
| Concept/Terms |
Medroxyprogesterone Acetate- Medroxyprogesterone Acetate
- Depo-Medroxyprogesterone Acetate
- Depo Medroxyprogesterone Acetate
- 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate
- 6 alpha Methyl 17alpha hydroxyprogesterone Acetate
- (6 alpha)-17-(Acetoxy)-6-methylpregn-4-ene-3,20-dione
- Medroxyprogesterone 17-Acetate
- Medroxyprogesterone 17 Acetate
|
Below are MeSH descriptors whose meaning is more general than "Medroxyprogesterone Acetate".
Below are MeSH descriptors whose meaning is more specific than "Medroxyprogesterone Acetate".
This graph shows the total number of publications written about "Medroxyprogesterone Acetate" by people in this website by year, and whether "Medroxyprogesterone Acetate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 2 | 1 | 3 |
| 2023 | 1 | 0 | 1 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Medroxyprogesterone Acetate" by people in Profiles.
-
The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin levels: A secondary study from the WHICH randomized clinical trial. PLoS One. 2024; 19(8):e0307736.
-
Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial. PLoS One. 2024; 19(5):e0299802.
-
Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial. PLoS One. 2024; 19(3):e0295764.
-
Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial. BMC Womens Health. 2024 Mar 08; 24(1):167.
-
Misreporting contraceptive use and the association of peak study progestin levels with weight and BMI among women randomized to the progestin-only injectable contraceptives DMPA-IM and NET-EN. PLoS One. 2023; 18(12):e0295959.
-
Contraceptive method preference and reasons for contraceptive discontinuation among women randomized to intramuscular depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant: Findings from Durban, South Africa. Contraception. 2022 04; 108:37-43.
-
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clin Pharmacol Ther. 2021 10; 110(4):1057-1065.
-
Effects of three contraceptive methods on depression and sexual function: An ancillary study of the ECHO randomized trial. Int J Gynaecol Obstet. 2021 Aug; 154(2):256-262.
-
Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant. Sex Transm Infect. 2021 06; 97(4):249-255.
-
Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. Clin Infect Dis. 2020 07 27; 71(3):517-524.